QIAGEN Files Lawsuit Against bioMérieux to Protect Key Innovations in TB Detection Technology

QIAGEN Files Lawsuit Against bioMérieux to Protect Key Innovations in TB Detection Technology

(IN BRIEF) QIAGEN has filed a lawsuit against bioMérieux in the German Unified Patent Court to protect its QuantiFERON technology, specifically its European Patent EP 2 276 883 B2, which covers innovations in QuantiFERON-TB Gold Plus used for TB detection. This legal action highlights QIAGEN’s commitment to safeguarding its intellectual property after successfully defending another QuantiFERON patent against an invalidity challenge. QuantiFERON-TB Gold Plus is recommended by global health organizations, including the WHO and CDC, for identifying individuals at risk of active tuberculosis. The technology plays a crucial role in preventing the spread of TB by detecting latent infections.

(PRESS RELEASE) VENLO, 3-Mar-2025 — /EuropaWire/ — QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) has filed a lawsuit against bioMérieux S.A. (EPA: BIM) in the German Unified Patent Court (UPC), asserting its intellectual property rights over key innovations in its QuantiFERON technology. This legal action reinforces QIAGEN’s ongoing commitment to safeguarding the proprietary advancements that power its QuantiFERON-TB Gold Plus, an essential tool in the global fight against tuberculosis (TB).

The complaint, lodged in the Local Division of the Unified Patent Court in Düsseldorf, Germany, concerns European Patent EP 2 276 883 B2. This patent is one of several QIAGEN holds to protect the QuantiFERON technology, which plays a critical role in the detection of latent tuberculosis through its widely used QuantiFERON-TB Gold Plus assay.

Thierry Bernard, CEO of QIAGEN, emphasized the importance of intellectual property protection, stating, “Safeguarding our intellectual property is vital for fostering continued innovation in the field of infectious disease diagnostics. QuantiFERON has revolutionized latent tuberculosis testing, and we will always take the necessary legal measures to defend our proprietary technologies from infringement.”

This lawsuit follows QIAGEN’s recent victory in defending a QuantiFERON-related patent against an invalidity challenge by SD Biosensor in Germany, further demonstrating the strength of the company’s extensive patent portfolio.

As a global leader in molecular diagnostics, QIAGEN remains committed to defending its intellectual property to ensure the security of its investments in innovation and to continue providing high-quality, reliable testing solutions for its customers worldwide.

QuantiFERON-TB Gold Plus (QFT-Plus) is highly recommended by prestigious health organizations such as the World Health Organization (WHO) and the U.S. Centers for Disease Control and Prevention (CDC) for identifying individuals at risk of developing active TB. Unlike traditional skin tests, QFT-Plus delivers more accurate, reliable, and objective results, making it a crucial tool in the global effort to control tuberculosis.

Latent TB infection occurs when the Mycobacterium tuberculosis bacteria remain dormant in the body, without symptoms, but it can progress to active TB, which is highly contagious and poses significant public health risks. Early detection and treatment of latent TB are essential to preventing the further spread of tuberculosis worldwide.

For further details on QuantiFERON technology and QIAGEN’s dedication to TB diagnostics, visit https://www.qiagen.com/us/applications/tb-management.

About QIAGEN

QIAGEN N.V., a Netherlands-based holding company, is the leading global provider of Sample to Insight solutions, enabling customers to extract and gain valuable molecular insights from samples containing the building blocks of life. Our Sample technologies isolate and process DNA, RNA and proteins from blood, tissue and other materials. Assay technologies prepare these biomolecules for analysis while bioinformatics software and knowledge bases can be used to interpret data to find actionable insights. Automation solutions bring these processes together into seamless and cost-effective workflows. QIAGEN serves over 500,000 customers globally in Life Sciences (academia, pharma R&D and industrial applications, primarily forensics) and Molecular Diagnostics for clinical healthcare. As of December 31, 2024, QIAGEN employed more than 5,700 people in over 35 locations worldwide. For more information, visit www.qiagen.com.

Forward-Looking Statement

Certain statements in this press release may constitute forward-looking statements within the meaning of Section 27A of the U.S. Securities Act of 1933, as amended, and Section 21E of the U.S. Securities Exchange Act of 1934, as amended. These statements, including those regarding QIAGEN’s products, development timelines, marketing and / or regulatory approvals, financial and operational outlook, growth strategies, collaborations and operating results – such as expected adjusted net sales and adjusted diluted earnings – are based on current expectations and assumptions. However, they involve uncertainties and risks. These risks include, but are not limited to, challenges in managing growth and international operations (including the effects of currency fluctuations, regulatory processes and logistical dependencies), variability in operating results and allocations between customer classes, commercial development for our products to customers in the Life Sciences and clinical healthcare, changes in relationships with customers, suppliers or strategic partners; competition and rapid technological advancements; fluctuating demand for QIAGEN’s products due to factors such as economic conditions, customer budgets and funding cycles; obtaining and maintaining regulatory approvals for our products; difficulties in successfully adapting QIAGEN’s products into integrated solutions and producing these products; and protecting product differentiation from competitors. Additional uncertainties may arise from market acceptance of new products, integration of acquisitions, governmental actions, global or regional economic developments, natural disasters, political or public health crises, and other “force majeure” events. There is also no guarantee that anticipated benefits from acquisitions will materialize as expected. For a comprehensive overview of risks, please refer to the “Risk Factors” contained in our most recent Annual Report on Form 20-F and other reports filed with or furnished to the U.S. Securities and Exchange Commission.

Media Contacts:

Dr. Thomas Theuringer
Senior Director Corporate Communications & Head Of External Communications
Germany: +49 2103 29 11826
Mobile: +49 1520 18 11826
thomas.theuringer@qiagen.com

Lisa Specht
Manager Public Relations
Germany: +49 2103 29 14181
Mobile: +49 152 01811381
lisa.specht@qiagen.com

SOURCE: QIAGEN